EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access

Genotype-Guided Antidepressant Prescribing for Patients With Depression

Kathryn V Blake, Lindsay J Hines, Michelle Liu, Rachel A Myers, Jordan F Baye, Kerri L Cavanaugh, Benjamin Q Duong, Leslie A Hulvershorn, Carol A Mathews, James W Murrough, Lori A Orlando, Natasha J Petry und 25 weitere

JAMA Network Open · 06.05.2026 · 9 (5) · e2610609

DOI: 10.1001/jamanetworkopen.2026.10609 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 06.05.2026. Verfasst von Kathryn V Blake und 36 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacogenomics and Translational Research, Nemours Children's Health, Jacksonville, Florida. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Depression. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The effectiveness of pharmacogenetics to guide prescribing of selective serotonin reuptake inhibitors (SSRIs) for depression remains unclear, despite the well-established association between SSRI pharmacokinetics and genetic variation.

Objective

To determine whether pharmacogenetic-guided prescribing of SSRIs improves treatment response in patients with depression. Design, Setting, and Participants The ADOPT PGx (A Depression and Opioid Pragmatic Trial in Pharmacogenetics) Depression pragmatic randomized clinical trial was conducted from August 10, 2021, through April 27, 2024, at primary care, psychiatry, or family medicine clinics at enrolling sites throughout the US. Patients were aged 8 years or older and had experienced depression for 3 months or longer.

Intervention

Patients were randomized to genotype-guided SSRI prescribing (intervention group) or usual care (control group). Actionable drug metabolism phenotypes were defined as those for which pharmacogenetic clinical guidelines recommend alternative medication selection or dose adjustment. Main Outcomes and Measures The primary outcome was change in Patient-Reported Outcomes Measurement Information System (PROMIS) depression T scores at 3 months among patients with the actionable phenotype. Secondary end points included adverse effect severity of SSRIs at 3 months and depression remission (measured with PROMIS depression scores and Patient Health Questionnaire-8 [PHQ-8] scores) at 6 months.

Results

This study of 1460 patients included 1239 adults (84.9%) (mean [SD] age, 40.6 [16.7] years) and 221 children (15.1%) (mean [SD] age, 14.6 [1.8] years). Most patients were female (1096 [75.1%]). A total of 692 patients (47.4%) had an actionable phenotype; 351 (50.7%) were assigned to the intervention, and 341 (49.3%) were assigned to usual care. At baseline, 463 of the 692 patients (66.9%) reported having depressive symptoms for more than 2 years, 603 (87.1%) were receiving pharmacologic treatment, and 354 (51.2%) were receiving nonpharmacologic treatment. At 3 months, no significant differences were observed between the intervention and usual care groups in change in PROMIS depression T scores (mean [SD] change, –4.3 [8.4] vs –4.0 [8.1]; P = .68), medication adverse effect burden (mean [SD] change, 8.2 [4.3] vs 7.8 [4.5]; P = .37), or Patient Health Questionnaire-8 score change (mean [SD] change, –3.3 [5.2] vs –2.7 [4.8]; P = .13). However, at 6 months, the PROMIS depression T-score remission rate (score ≤16) was higher in the intervention group compared with the usual care group (153 of 317 patients [48.3%] vs 122 of 310 patients [39.4%]; P = .02). Conclusions and Relevance In this randomized clinical trial, genotype-guided prescribing of SSRIs did not improve control of depression symptoms at 3 months compared with usual care but was associated with higher depression remission rates at 6 months. These findings suggest a possible longer-term clinical benefit and indicate that future studies should focus on the durability and long-term impact of genotype-guided prescribing in the management of depressive symptoms. Trial Registration ClinicalTrials.gov Identifiers: NCT04445792 (Master Protocol Research Program platform trial) and NCT05966155 (ADOPT PGx Depression trial)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsAntidepressive AgentsDepressionHumansFemaleMaleAdultMiddle AgedGenotypeTreatment OutcomePatient Reported Outcome Measures

Substanzen

Selective Serotonin Reuptake InhibitorsAntidepressive Agents

Autor:innen und Institutionen

  • Center for Pharmacogenomics and Translational Research, Nemours Children's Health, Jacksonville, Florida.
  • Department of Psychology, University of North Dakota, Grand Forks.
  • Brain and Spine Center, Sanford Health, Fargo, North Dakota.
  • Department of Pharmacy Practice, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Clinical Research Unit, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Department of Pharmacy Practice, South Dakota State University, Brookings.

Förderung

  • NIDDK NIH HHS
  • NHGRI NIH HHS

Zitieren

APA

Blake, K. V., Hines, L. J., Liu, M., Myers, R. A., Baye, J. F., Cavanaugh, K. L., Duong, B. Q., Hulvershorn, L. A., Mathews, C. A., Murrough, J. W., Orlando, L. A., Petry, N. J., Tillman, E. M., Sadeghpour, A., Voora, D., Block, S. L., Cicali, E. J., Clermont, S., Elwood, E. N., …, & IGNITE Pragmatic Trials Network (2026). Genotype-Guided Antidepressant Prescribing for Patients With Depression. JAMA Network Open, 9(5), e2610609. https://doi.org/10.1001/jamanetworkopen.2026.10609

Vancouver

Blake KV, Hines LJ, Liu M, Myers RA, Baye JF, Cavanaugh KL, et al. Genotype-Guided Antidepressant Prescribing for Patients With Depression. JAMA Network Open. 2026;9(5):e2610609. doi:10.1001/jamanetworkopen.2026.10609

BibTeX
@article{Blake2026,
  author = {Blake, Kathryn V and Hines, Lindsay J and Liu, Michelle and Myers, Rachel A and Baye, Jordan F and Cavanaugh, Kerri L and Duong, Benjamin Q and Hulvershorn, Leslie A and Mathews, Carol A and Murrough, James W and Orlando, Lori A and Petry, Natasha J and Tillman, Emma M and Sadeghpour, Azita and Voora, Deepak and Block, Sara L and Cicali, Emily J and Clermont, Sabrina and Elwood, Erica N and Harris, Elizabeth C and Nguyen, Khoa A and Ramos, Michelle A and Rosenman, Marc B and Shroff, Nandini and Shuman, Saskia and Wyatt, Christina and Horowitz, Carol R and Volpi, Simona and Singh, Rajbir and Rider, Renee A and Chakraborty, Hrishikesh and Dexter, Paul R and Johnson, Julie A and Skaar, Todd C and Cavallari, Larisa H and Peterson, Josh F and IGNITE Pragmatic Trials Network, IGNITE Pragmatic Trials Network},
  title = {Genotype-Guided Antidepressant Prescribing for Patients With Depression},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {e2610609},
  doi = {10.1001/jamanetworkopen.2026.10609}
}
Kostenlos starten →